Veracyte (VCYT) CFO trades shares as RSUs vest and 10b5-1 plan executes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported recent transactions in the company’s common stock. On June 4, 2026, she executed two open-market sales totaling 3,561 shares at weighted average prices of $49.2836 and $50.0913 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2025.
Separately, on June 2, 2026, 3,693 shares were withheld to cover tax obligations upon the vesting of restricted stock units; this was not an open-market sale. After these transactions, Chambers directly holds 173,280 shares of Veracyte common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 3,561 shares ($177,083)
Net Sell
3 txns
Insider
Chambers Rebecca
Role
Chief Financial Officer
Sold
3,561 shs ($177K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,600 | $49.2836 | $79K |
| Sale | Common Stock | 1,961 | $50.0913 | $98K |
| Tax Withholding | Common Stock | 3,693 | $47.80 | $177K |
Holdings After Transaction:
Common Stock — 175,241 shares (Direct, null)
Footnotes (1)
- Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. Represents weighted average sales price. Sale prices for the transactions range from $48.80 to $49.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $49.88 to $50.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Key Figures
Open-market sale 1: 1,961 shares at $50.0913
Open-market sale 2: 1,600 shares at $49.2836
Total shares sold: 3,561 shares
+2 more
5 metrics
Open-market sale 1
1,961 shares at $50.0913
Common Stock sale on June 4, 2026
Open-market sale 2
1,600 shares at $49.2836
Common Stock sale on June 4, 2026
Total shares sold
3,561 shares
Net open-market sales reported in Form 4
Tax withholding shares
3,693 shares at $47.80
Withheld for RSU tax obligations on June 2, 2026
Post-transaction holdings
173,280 shares
Direct ownership after reported transactions
Key Terms
Rule 10b5-1 plan, restricted stock units, weighted average sales price
3 terms
Rule 10b5-1 plan financial
"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock units financial
"tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sales price financial
"Represents weighted average sales price. Sale prices for the transactions range from $48.80 to $49.74."
FAQ
What insider transactions did Veracyte (VCYT) CFO Rebecca Chambers report?
Rebecca Chambers reported two open-market sales totaling 3,561 Veracyte shares on June 4, 2026, plus 3,693 shares withheld on June 2, 2026 for tax obligations related to restricted stock unit vesting, which the company clarifies did not constitute an open-market sale.
Were the Veracyte (VCYT) CFO’s stock sales made under a Rule 10b5-1 plan?
Yes. The Form 4 notes that the reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2025, indicating the sales were pre-arranged rather than timed on an ad hoc basis.